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Definition and epidemiology:  
The burden of hyperuricemia is rising
The definition of hyperuricemia (HU) varies 
widely in different studies, which makes the epi-
demiological reports somewhat inconsistent. HU 
remains the culprit of the pathogenesis of gout 
which occurs in 3–6% of men and 1–2% of women 
from Western countries [1]. The linear relation-
ship between serum uric acid (sUA) levels and 
the risk of gout have been demonstrated in many 
studies and registries including the large-scale 
Framingham study and Normative Aging study in 
the United States of America (USA) [1]. The United 
States National Health and Nutrition Examination 
Survey (NHANES) study estimated the prevalence 
of gout to be 3.9% (5.9% for men, 2.0% for women) 
and the HU prevalence to be 21.4% (21.2% for men 
and 21.6% for women) [2]. 
The prevalence of HU depends on sex age and 
ethnicity, reaching a plateau at the age of 70. At 
variance from USA and other Western countries 
(see above) in developing countries, it occurs in 
less than 1% of the general population, but this 
may represent an underestimation of the true pre-
valence due to insufficient epidemiological data [3] 
and a very high prevalence has been found in 
some developing subsets of the population, such 
as, for example, the Taiwanese aboriginals (41%). 
Reports are also available of ethnic difference such 
as, in the USA, a higher prevalence among African 
Americans than among non-African Americans 
(25.7%, 22.1%, respectively) [4]. Over the 10 
years, epidemiological data consistently show an 
increase in the prevalence of both HU and gout. 
This might be caused by rapid economic develop-
ment and a change of dietary habits and lifestyle 
and among patients with a higher socioeconomic 
status [5, 6]. Interestingly, sUA levels are higher 
in subsets of subjects at high cardiovascular (CV) 
risk, including postmenopausal women, non-white 
patients with hypertension or chronic kidney dis-
ease (CKD). The adoption of western lifestyle by 
natives of other countries and cultures together 
with a change in the socioeconomic background 
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as movements from rural to urban communities, 
has influenced sUA levels [7, 8]. Currently, > 1.2 
million patients in the USA and United Kingdom 
are being prescribed allopurinol, the xanthine 
oxidase inhibitor (XOI), which successfully lowers 
their sUA level [9].
The relationship between  
hyperuricemia and gout
Although the definition of asymptomatic HU 
is still being discussed, it is after all merely, 
a biochemical disorder. Gout is a chronic disease 
with periods of inflammation, also known as flares, 
which are caused by the deposition of monoso-
dium urate (MSU) crystals as a result of HU [10]. 
The crystallization of MSU in vitro takes place at 
a concentration of ≥ 6.8 mg/dL (temperature of 
37°C) or > 6.0 mg/dL (temperature of 35°C) sUA 
at pH 7.0. This process may occur at a lower sUA 
concentration at lower pH levels and at a lower 
tissue temperature in peripheral joints. The reso-
lution of tophaceous deposits occurs when sUA 
level is < 5 mg/dL [11]. Subsequently, the host’s 
inflammation response to the deposited crystals 
shows clinical symptoms of gout [12]. 
Although the presence of HU is essential for 
the formation of crystals, only part of the patient 
population with HU develop gout i.e. 2–36% of 
patients in studies with a 5–10-year period of 
follow-up [13, 14]. Thus, the finding of HU is not 
sufficient to diagnose gout. Conversely, Schles-
inger et al. [15], confirmed a “true” normal sUA 
level (≤ 6 mg/dL) in 14% of patients suffering 
from an acute attack of gout. Interestingly, gout 
is unlikely in patients with a low sUA level, even 
when a confirmed normal sUA level occurs during 
an acute flare [16]. This indicates a more complex 
relationship between sUA levels and gout flares. 
Thus, the definition based on the solubility of UA 
may need to be fundamentally reconsidered [4]. 
High sUA levels are predominantly caused by 
an insufficient elimination (90%) or overproduction 
(10%) of sUA. Therefore, the aim of the treatment 
is dissolution and prevention of further formation 
of MSU crystals. 
Since different mechanisms interact with the 
pathogenesis of gout, the clinical presentation of 
the disease is heterogeneous. This includes the 
genesis of elevated sUA, the process of crystal 
formation and growth, and subsequent inflamma-
tion, activated by MSU crystals. In fact, four stages 
can be distinguished in the development of gout: 
i) HU without symptoms of MSU deposition; 
ii) deposition of MSU crystals without sympto-
matic gout; iii) deposition of MSU crystals with 
acute exacerbations of gout; iv) advanced gout 
characterized by the occurrence of gouty nodules 
(the effect of an organized, chronic inflamma-
tory reaction involving interleukin 1b, TNF-a, 
and TGF-b1), chronic arthritis and joint damage 
identified in radiological reports. In the absence of 
adequate treatment, advanced gout usually appears 
approximately 10 years after the first “flare-up”. 
This mostly occurs in the distal part of the lower 
limb (i.e., first metatarsophalangeal joint), and un-
dergoes spontaneous resolution within 1–2 weeks. 
In the absence of adequate treatment, flares occur 
more frequently affecting more and more joints. 
Ultimately the disease changes to stage 4 with the 
onset of tophi and joint inflammation [17].
A large body of evidence describes the link 
between HU, CKD and cardiovascular disease 
(CVD). Undoubtedly, cardiovascular and renal 
comorbidities play a key role in the management 
strategies of patients with HU and gout. 
The pathophysiological effect  
of HU on CVD: Purine catabolism,  
oxidative metabolism, inflammation,  
“uric acid paradox”
The primary baseline risk factor for HU in 
patients is a mutational inactivation of a gene for 
uricase, an enzyme which degrades urate to the 
more soluble allantoin [18]. Notwithstanding, to 
generate HU, additional risk factors are required. 
First and foremost, an increased sUA level is 
the result of a purine/fructose-rich diet, genetic or 
environmental factors, metabolic disorders, as well 
as its endogenous overproduction or, in most cases, 
by insufficient excretion (Fig. 1). The synthesis 
is mainly affected by phoribosyl-pyrophosphate 
synthetase or purine salvage pathway influenced 
by hypoxanthine-xanthine phosphoribosyl trans-
ferase. Fructose causes mostly the depletion of 
ATP increasing the generation and release of UA 
[19]. An excessive purine turnover may be present 
in some clinical scenarios, comprised of leukemias, 
hemolytic anemias, etc. On the other hand, ca. 90% 
of UA is reabsorbed in the proximal tubular cells 
by urate-anion transporter 1 (URAT-1) and organic 
anion transporters (OATs) clustered in the renal 
cortex according to their roles as reuptake- or se-
cretory transporters (Fig. 2) [20, 21]. The natural 
mechanism of further breakdown of UA is impos-
sible due to the lack of human uricase (hominids 
lost expression of gene encoding, therefore, they 
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cannot convert UA to allantoin) [22]. Thus, it is the 
kidneys that may play a key role in the process of 
underexcretion. 
Impaired oxidative mechanism
The increased activity of xanthine oxidase 
(XO) influences the XO-derived reactive oxygen 
species (ROS) formation resulting in vascular 
endothelial dysfunction. This is the case when an 
increased catabolism of purines and subsequent 
UA production xanthine oxidoreductase converts 
intensively hypoxanthine to xanthine and xanthine 
to UA. Xanthine oxidoreductase exists in two iso-
forms: xanthine dehydrogenase and XO. XO uses 
molecular oxygen as an electron acceptor, thus, 
generating superoxide anion and other reactive 
oxygen species as by-products which can trigger 
endothelial dysfunction (e.g. reduces endothe-
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Figure 1. Pathophysiological aspects of hyperuricemia and its influence on cardiovascular and kidney disease; 
ABCG2 — ATP binding cassette multidrug transporter; CAD — coronary artery disease; eGFR — estimated glomerular 
filtration rate; HDL — high density lipoprotein; LDL — low density lipoprotein; NO — nitric oxide; PAD — peripheral 
arterial disease; ROS — reactive oxygen species; RBF — renal blood flow; URAT-1 — uric acid transporter 1; VSMC 
— vascular smooth muscle cells.
lial nitric oxide [NO] production) and thereby 
contribute to the incidence of hypertension and 
target organ damage. Circulating and endothelial-
bound XO is over-expressed in ischemic tissues. 
Oxidative stress generated by XO overactivity has 
a detrimental effect on the vascular endothelium in-
cluding coronary arteries [23, 24]. Thus, increased 
sUA levels impair an oxidative metabolism, stimu-
lating the renin–angiotensin system and inhibits 
the release of endothelial NO. This contributes 
to, microvascular damage to afferent arterioles, 
renal vasoconstriction and, permanent sodium-
sensitive hypertension [25, 26]. Persistent renal 
vasoconstriction may contribute to arteriolosclero-
sis and the development of primary hypertension. 
Indeed, in many experimental studies, UA induces 
vascular smooth-muscle cell (VSMC) proliferation, 
inflammation processes, oxidative stress and, con-
sequently, local renin–angiotensin system activity 
[27–29]. Whether hypertension exists or not, the 
influence of an increased level of sUA on endothe-
lial cells and VSMC develops microvascular renal 
disease [28, 30, 31]. On one hand, preglomerular 
arteriolar disease impairs renal autoregulatory 
response and glomerular hypertension. On the 
other in diabetic patients, elevated sUA levels are 
a well-known predictor of microalbuminuria and 
renal dysfunction [32, 33] being associated with 
an impaired glomerular filtration rate (GFR) [34].
Lastly, preclinical research supports the hy-
pothesis that both endothelial dysfunction and the 
inflammatory and oxidative changes in adipocytes 
which remain the key factors in causing metabolic 
syndrome [35]. Some studies reported an associa-
tion between sUA levels, obesity, and insulin resist-
ance. Subsequently, HU has even been proposed, as 
a component of metabolic syndrome [36]. Although 
UA has an inflammatory and prooxidative effect on 
vascular cells and adipocytes, in some neurologic 
disorders, i.e., multiple sclerosis or Parkinson’s 
disease, it may function as an antioxidant thus being 
protective. Many scientists focus on low-grade sys-
temic inflammation, XO activity, or the unfavorable 
effects of HU [37], however, the entire mechanism 
that links these diseases is not fully understood.
Genetics and the environment:  
Individualized diagnosis and care  
strategy. Key advances in the  
understanding of factors associated  
with an increased risk of HU 
In the development of HU, the influence of 
genetics and environmental factors, cannot be ig-
nored [38]. The inheritance of sUA levels and the 
fractional excretion of urate have been reported 
in studies which examine the phenotypic relation-
ship between twins and establish it as 43–73% and 
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Figure 2. Renal proximal tubule urate transportasome; ABCG2 — ATP binding cassette multidrug transporter; 
OAT — organic anion transporter; URAT-1 — uric acid transporter 1.
46–96%, respectively [38, 39]. Indeed, genome-wide 
association studies identified the genetic basis of HU 
as dominated by loci containing urate transporters 
and interacting proteins involved in the excretion 
of urate (SLC2A9, ABCG2, SLC22A11, SLC17A1– 
–SLC17A4 and PDZK1) and proteins associated with 
metabolic pathways (e.g. GCKR, A1CF, IGF1R). For 
instance, reduced intestinal excretion is associated 
with polymorphisms of the ABCG2 gene [40]. Con-
sequently, some research has shown a relationship 
between a genetic risk score of a high sUA and CV 
death or renal function [41, 42]. In other studies, 
a different SNP in the SLC2A9 gene was associated 
with an increased sUA level and normal blood pres-
sure (BP) or hypertension [43, 44]. Since sUA is 
a result of the effects of inherited genetic variation 
especially on kidneys, gastrointestinal tracts and/or 
the liver and different processes, further specialized 
genome-wide association studies is required.
Currently, the explanation of the genetic impact 
on the development of gout from HU is still insuf-
ficient. First and foremost, genes encoding proteins 
are involved in the NLRP3 (NOD-, LRR- and pyrin 
domain-containing 3) inflammasome pathway feature 
[45]. The genetic effect depending on glycolysis 
genes as well as the interactions between genes 
and environmental factors — i.e., diuretics, alco-
hol — have already been researched. Interestingly, 
genome-wide and targeted sequencing revealed the 
population-specific and penetrant genetic variants. 
Which have provided insight into the pathogenesis of 
gout, as well as the prediction of likely responsiveness 
to urine-lowering therapy [45]. These advances lead 
to individualized patient care. Genetic data can inform 
about the prognosis in patients suffering from HU, 
and help clinicians in their selection and dosage of 
urate-lowering therapy (ULT) and the correct advice 
on lifestyle changes.
Environmental factors that influence HU in-
clude diet and medication: i.e. probenecid, benzbro-
marone and sulfinpyrazone and the XOI allopurinol, 
febuxostat, antihypertensive drugs, cholesterol-
lowering therapy, steroid medication, some non-
steroidal anti-inflammatory drugs and antibiotics 
as well as small doses of acetylsalicylic acid and 
thiazides (Table 1). A high intake of the following: 
meat, seafood, fructose, alcohol, and sodium are 
known to increase sUA levels. 
Hyperuricemia and comorbidities:  
A high sUA level and cardiovascular risk
Uric acid remains an end-product of purine 
catabolism and is considered, an independent factor 
for the development of a wide variety of microvas-
cular and macrovascular disorders: hypertension 
[46], metabolic syndrome [47, 48], coronary artery 
disease (CAD) [49], diabetes [50], cerebrovascular 
disease [51, 52] and CKD (Fig. 1) [53] as well as 
other CVDs [54, 55] and, conversely, these comor-
bidities increase the incidence of HU [4].
As mentioned above, the risk of crystallization 
of MSU increases when the saturation of sUA is > 
6.8 mg/dL [18]. This induces the localized inflam-
matory reactions in joints and connective tissue 
[56] leading to gout, in up to 36% of HU-patients 
within a period of 5–10 years [13, 14]. However, 
some studies reported a relation between sUA level 
and CVD not only in patients with clearly diagnosed 
HU, but also with values considered as normal 
to high, i.e. > 5.2–5.5 mg/dL [57–59]. Notably, 
since a high sUA concentration is associated with 
inflammatory markers, i.e. C-reactive protein or 
neutrophil count, inflammation seems to be a major 
link between HU and CVD and kidney diseases [4].
Patients with HU or gout require systematic 
screening for diseases associated with high sUA 
concentrations. A large body of evidence confirms 
the contribution of HU in the worsening of car-
diovascular, diabetic, lipid and renal diseases [41, 
60, 61]. Thereby supporting the evidence that an 
increased sUA level indicates an emerging CV 
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Table 1. Drug effect on the serum level of uric 
acid [4].
Acetylsalicylic acid ≠ (at low doses) 
Ø (at high doses)
Clopidogrel ´
Ticagrelor ≠
Beta-blockers (propranolol,  
atenolol, metoprolol, timolol)
≠
ACEIs and ARBs ´
Losartan Ø
Diuretics (loop diuretics,  
thiazide-type diuretics,  










≠ — increase; Ø — decrease; ACEIs — angiotensin-converting  
enzyme inhibitors; ARBs — angiotensin receptor blocker;  
SGLT2 — sodium glucose cotransporter 2
risk [62, 63]. Therefore, the management of such 
conditions should be an integral part of a patients’ 
treatment strategy (Tables 2 and 3) [4, 64–66]. 
In the NHANES, which included 5707 partici-
pants aged 20 years and above, hypertension was 
diagnosed in 74% of patients, CKD in 71%, obesity 
(body mass index [BMI] ≥ 30 kg/m2) in 53%, type 2 
diabetes in 26%, nephrolithiasis in 24%, past 
myocardial infarction (MI) in 14%, chronic heart 
failure (HF) in 11%, had suffered a stroke 10% 
[67]. The negative results mentioned above were 
more frequent in patients with HU than in patients 
without. In the group of patients with a sUA level 
of > 10 mg/dL, these conditions were even more 
frequent, i.e.: 86% of patients suffered from chronic 
disease, 66% hypertension, 65% obesity, 33% HF, 
33% type 2 diabetes, 23% past MI, and 12% had 
suffered a stroke in the past. 
Hyperuricemia and hypertension
It has been known for a while, that renal 
injury can be caused by advanced arteriosclero-
sis, glomerulosclerosis, interstitial fibrosis, i.e. 
a deposition of urate crystal. This was reflected 
in a majority of patients with HU/gout who suf-
fered from hypertension and were in an older age 
group [68]. One of the hypothesis attributes HU 
in hypertension to an impaired urate clearance and 
tubular secretion [69] as a result of a reduced renal 
blood flow [70] with an impaired delivery of urate 
to the sites of tubular secretion in the peritubular 
space. Nevertheless, recent preclinical and clinical 
studies consistently support the hypothesis that 
increased levels of sUA may lead to hypertension 
[27, 50, 71–82]. Remarkably, HU is more frequent 
in primary hypertension vs. white-coat or second-
ary hypertension [57]. Moreover, it is common 
among patients with prehypertension or microal-
buminuria [32, 83].
An ample body of evidence widely acknowl-
edged that the association between an increase in 
the relative risk of hypertension and high levels 
of sUA remains independent of traditional risk 
factors [77, 79, 84–90]. Interestingly, the as-
sociation between sUA, hypertension and CVD 
remain stronger in women, younger patients, and 
patients with fewer CV risk factors [4]. In a large 
meta-analysis involving 18 studies (n = 55,607), 
Grayson et al. [84] confirmed that there is an 
increase of 13% in the incidence of new-onset hy-
pertension for every increase of 1% in sUA level. 
Kubawara et al. [91] in their retrospective cohort 
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Table 3. Prevalence of comorbidities according to hyperuricemia and gout in National Health and  
Nutrition Examination Survey (NHANES US) 2007–2008 [67].
Comorbidities Hyperuricemia
Gout 
Prevalence, % (95% CI)
No gout 
 Prevalence, % (95% CI)
Hypertension 77.7 (66.6–88.8) 47.2 (43.0–51.4)
CKD stage ≥ 2 71.8 (61.3–82.3) 70.4 (62.8–78.0)
Obesity — BMI 30 kg/m2 55.6 (45.5–65.7) 54.2 (49.0–59.4)
Diabetes 26.9 (9.7–44.1) 12.2 (8.7–15.6)
CKD stage ≥ 3 22.6 (14.0–31.2) 17.4 (13.2–21.5)
Nephrolithiasis 20.2 (10.3–30.2) 11.6 (8.9–14.3)
Stroke 11.8 (0.4–23.1) 5.1 (3.6–6.7)
Heart failure 11.7 (6.1–17.4) 4.5 (3.4–5.5)
Myocardial infarction 11.6 (4.5–18.7) 4.5 (3.3–5.6)
Depicted are n prevalence (%) and 95% confidence interval (CI).
BMI — body mass index; CKD — chronic kidney disease; GFR — glomerular filtration rate
CKD stage ≥ 2 = GFR < 60 mL/min/1.73 m2 and ≥ 30 mL/min/1.73 m2; CKD stage ≥ 3 = GFR < 30 mL/min/1.73 m2 and ≥ 15 mL/min/1.73 m2
Table 2. Diseases associated with hyperuricemia, 
requiring clinical evaluation in patients  
diagnosed with hyperuricemia.
Excessive alcohol consumption, lead poisoning
Lipid disorders, modifiable risk factors for  
coronary disease/stroke
Use of drugs increasing serum uric acid
Obesity
Metabolic syndrome, type 2 diabetes
Kidney stones in past medical history
Chronic kidney disease 
Hypertension
study (n = 3584) reported sUA level as a strong 
risk marker for the development of hyperten-
sion from prehypertension. The cumulative inci-
dence of hypertension from prehypertension over 
5 years was 25.3%, and the cumulative incidence 
of hypertension in subjects with HU (n = 726) 
was significantly higher than in those without HU 
(n = 2858; 30.7% vs. 24.0%; p < 0.001). In the 
Pressioni Arteriose Monitorate e Loro Associazioni 
(PAMELA) study, 2045 participants underwent 
a complex assessment of CV risk which included 
sUA level, metabolic, renal and anthropometric 
variables, left ventricular (LV) mass index, as well 
as the measurement of, home, office, and ambula-
tory BP. Patients were monitored for an average 
of 16 years. The new-onset of hypertension was 
recognized in patients with systolic BP (SBP) or 
diastolic BP (DBP) exceeding the upper normal-
ity levels. On subsequent examination or after 
introducing antihypertensive therapy an increase 
of sUA by 1 mg/dL was associated with a signifi-
cant increase in the risk of developing new-onset 
home and ambulatory hypertension (odds ratio 
[OR] 1.34, 95% confidence interval (CI) 1.06–1.7, 
p = 0.015; OR 1.29, 95% CI 1.05–1.57, p = 0.014, 
respectively) [85]. Notably, this was the first study 
to include a measurement of sUA level among the 
factors included in the algorithm assessing the 
total CV risk [61].
Hyperuricemia and metabolic syndrome
As mentioned above, several studies demon-
strated that sUA level is associated with metabolic 
syndrome, high BMI, waist circumference, high 
fasting blood glucose levels, and dyslipidemia [92]. 
These results, and the fact that targeting high 
levels of serum low-density lipoprotein (LDL) is 
beneficial for patients at CV risk prompted other 
groups to investigate whether HU predicts an 
increase in LDL cholesterol. Actually, Kuwabara 
et al. [61] confirmed that elevated sUA increased 
the risk of developing high LDL cholesterol in 
both men (OR 1.159 per 1 mg/dL increase, 95% 
CI 1.009–1.331, p = 0.037) and women (OR 1.215, 
95% CI 1.061–1.390, p = 0.005), as well as hyper-
triglyceridemia.
Hyperuricemia and chronic kidney disease: 
“What comes first?”
First observations of the possible causative 
role of sUA on CKD were confirmed in large 
studies, including, the NHANES and the German 
Chronic Kidney Disease (GCKD) study [93, 94]. 
Data from the German registry documented gout in 
24.3% of patients with CKD. The prevalence of gout 
was substantially higher in patients with estimated 
GFR (eGFR) of < 30 mL/min/1.73 m2 vs. ≥ 60 mL/ 
/min/1.73 m2 [94]. The meta-analysis, which included 
18 prospective studies (n = 431,000), revealed that 
HU predicts the occurrence of CKD and GFR decline 
[95]. Indeed, HU plays a key role in the development 
and progression of CKD. It remains an independent 
factor in the progression of CKD, even after making 
adjustment for classic comorbidities such as hyper-
tension, proteinuria, and dyslipidemia. This relation-
ship was confirmed in IgA nephropathy, diabetes 
nephropathy, renal transplantation, or autosomal-
dominant polycystic kidney disease [96–99]. Notably, 
in normotensive patients, with normal renal function, 
the association between sUA and the likelihood of 
a decrease in eGFR was noted. This effect was ap-
parent at a concentration level of sUA of 5.5 mg/dl, 
5.0 mg/dL in women [100].
Since the pathogenesis of HU is complex and 
lots of conflicting factors influencing CKD are 
well described, the question “what comes first?” 
remains open [95]. It is worth noting, that hyper-
tension can cause CKD and, subsequently, there is 
a decline in renal function. Moreover, the diuretic 
therapy may essentially increase the sUA levels. 
However, the studies based on healthy subsets 
revealed a clear association between sUA and CKD 
in long-term observation [53, 101]. 
“Uric acid paradox”
Despite the well-known association between 
HU and CAD, high sUA levels are strongly associ-
ated with peripheral carotid vascular disease and 
vascular dementia [51, 102]. 
In a study by Ruggiero et al. [103] (n = 1016), 
it was found that elderly patients with dementia 
had higher concentrations of sUA. Patients with 
the highest sUA concentrations had a higher prob-
ability to develop dementia (OR 3.32, 95% CI 1.06–
–10.42) [103]. Contrarily, some studies revealed 
that HU might reduce the risk of neurological 
diseases, especially Parkinson’s and Alzheimer’s 
disease, vascular and non-vascular dementia [104] 
or osteoporosis [105]. This so-called “uric acid 
paradox” has already been widely discussed [4].  
Hyperuricemia and adverse events:  
A high sUA level and its influence  
on cardiovascular outcome 
Hyperuricemia and mortality
The Third NHANES presented an increased 
risk of all-cause death and cardiac death in 
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patients with an increased sUA level. The associa-
tion remained significant even after adjustment for 
different factors including demography and comor-
bidities [106]. In the PAMELA study, patients were 
randomly recruited from the general population 
and underwent a thorough assessment of CV risk, 
including an echocardiogram and out-of-office BP 
measurement. The analysis suggested that the 
cut-off sUA level which showed the best trade-off 
between sensitivity and specificity of risk prediction 
were 5.4 mg/dL for CV mortality and 4.9 mg/dL for 
all-cause mortality [85]. Data from the Preventive 
Cardiology Information System (PreCIS) database 
documented that for each 1-mg/dL increase in the 
sUA level, there was a 39% increase in the risk of 
death. After adjusting for age, sex, weight, BMI, 
waist circumference, BP, history of CVD, eGFR rate, 
levels of cholesterol fractions, and plasma glucose 
levels, smoking status, and alcohol consumption, the 
sUA level continued to accurately predict the risk 
of death (hazard ratio [HR] 1.26, 95% CI 1.15–1.38, 
p < 0.001). Notably, the association occurred wheth-
er the patient was taking diuretics or not.
Interestingly, sUA level significantly improved 
the predictive accuracy of a model that included 
Framingham Heart Study score factors, compo-
nents of metabolic syndrome, and fibrinogen level 
[107]. In a group of 51,297 male patients included 
in the Health Professionals Follow-Up Study, those 
suffering from gout had a higher risk of all-cause 
death. Curiously, among men without preexisting 
CAD, the increased mortality risk was primarily 
a result of an elevated risk of CVD death. Addition-
ally, men with gout had a higher risk of nonfatal 
MI than men without gout (relative risk [RR] 1.59; 
95% CI 1.04–2.41) [108]. In a much larger study 
that included 354,110 subjects without a history 
of gout at the Chang Gung Memorial Hospital in 
Taiwan, patients with both high and low sUA levels 
were at higher risk of all-cause and cardiovascular 
mortality [109]. The increased risk of death was re-
ported among patients with a high sUA level and HF 
[110]. A large retrospective analysis of patients with 
symptomatic HF revealed that HU was significantly 
associated with increased HF events or death [111].
Hyperuricemia and acute myocardial  
infarction and risk of strokes
Krishnan et al. [112] confirmed the independ-
ent risk relationship between HU and acute MI. 
Interestingly, gouty arthritis was associated with an 
excess risk of acute MI, which was not explained by 
its well-known links with other comorbidities, i.e., 
renal function, metabolic syndrome, traditional CV 
risk factors as well as diuretic therapy. These results 
have prompted further research in which sUA levels 
and untreated gout were documented as independent 
prognostic markers for poor all-cause and cardiac 
mortality in patients with recent acute MI [112].
In the Rotterdam Study (n = 4385), among 
patients without a history of MI or who had suf-
fered strokes at baseline, high sUA levels were 
associated with long-term risk of MI and strokes; 
an age and sex-adjusted hazard ratios (95% CI) 
for highest versus lowest quintile of sUA were 
1.68 (1.24–2.27) for CVD, 1.87 (1.12–3.13) for MI, 
1.57 (1.11–2.22) for strokes, 1.77 (1.10–2.83) for 
ischemic strokes, and 1.68 (0.68–4.15) for hemor-
rhagic strokes [102]. Tscharre et al. [113] suggest 
an independent association of HU (defined as UA 
levels > 6.0 mg/dl in women, and > 7.0 mg/dl in 
men) with long-term major adverse cardiovascular 
event (MACE), including CV death, MI and strokes, 
in acute coronary syndrome patients undergoing 
percutaneous coronary intervention. Patients 
with HU had a 1.6-fold increased RR for CV death 
(p = 0.005) and a 1.5-fold increased risk for MI 
(p = 0.032) [113]. In a small study (n = 140), the 
prevalence of moderate-to-severe coronary calci-
fication in CAD was more severe in hyperuricemic 
patients with asymptomatic MSU crystal deposi-
tion than normouricemic or hyperuricemic patients 
without such deposits [114].
In an analysis of the large Swedish registry (n 
= 417,734) of a group of patients undergoing health 
check-ups, moderate levels of sUA appeared to be 
associated with an increased incidence of acute MI, 
stroke and congestive HF in middle-aged subjects 
without prior CVD [115]. Finally, sUA level was posi-
tively associated with the presence (p = 0.0001), 
the number (p = 0.001), the size (p = 0.001), and 
the location of lacunar infarcts (LI) in the basal 
ganglia (p = 0.0038), the deep white matter (DWM) 
(p < 0.0001), and the pons (p = 0.0156). Pathologi-
cally, it was characterized by arteriolosclerosis and 
atherosclerosis. Interestingly, the occurrence of 
LI increased starting from sUA levels of 5.7 mg/dl 
[116]. HU may substantially increase the risk of 
a stroke, even in patients at a low risk of atrial fi-
brillation, thus, may constitute an independent risk 
factor for strokes in a hyperuricemic setting.
Hyperuricemia treatment and  
cardiovascular outcomes:  
Allopurinol and febuxostat
Xantine-oxidase inhibitors, especially allopu-
rinol, are currently recommended as a first-line 
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ULT. However, the optimism related to febuxostat 
has been dispelled by recently published results 
from the Cardiovascular Safety of Febuxostat and 
Allopurinol in Patients with Gout and Cardiovas-
cular Morbidities (CARES) study [117].
Allopurinol: The influence  
of XOI on cardiovascular outcomes
Allopurinol and mortality
Knowledge of the effectiveness of XOI makes 
them a subject of major interest [118–126]. How-
ever, the causality between HU/gout and these 
CV outcomes remains controversial, mainly due 
to confounding variables and common etiological 
factors [4, 126-128].
The effect of purine XOI on all-cause mortality 
and CV mortality is probably due to its potent anti-
oxidant effect, which has the ability to inhibit reac-
tive oxygen species production [129, 130]. Among 
potential mechanisms, it should be stressed that 
endothelial dysfunction and low-grade inflamma-
tion can occur as a major negative factor [7, 131]. Of 
note, at high concentrations, XO promotes oxida-
tive stress and emphasizes endothelial dysfunction. 
Increasing evidence exists to suggest the crucial 
role of XO in various forms of ischemic and other 
types of tissue and vascular injury, inflammatory 
processes and chronic HF [132].
In a record-linkage database (n = 7135), CV 
event rates were 74.0 (95% CI 61.9–86.1)/1000-per-
son-years in the 100 mg allopurinol group, 69.7 
(95% CI 49.6–89.8) in the 200 mg allopurinol 
group and 47.6 (95% CI 38.4–56.9) in the ≥ 300 mg 
allopurinol group [133]. Moreover, high-dose al-
lopurinol, defined as ≥ 300 mg/dL vs. < 299 mg/dL, 
was associated with a reduced risk of all-cause 
mortality (adjusted HR 0.65, 95% CI 0.42–0.99) 
[7, 134]. In the large-scale cohort study by Dubreuil 
et al. [135] the initiation of allopurinol therapy was 
associated with an 11% lower risk of all-cause death 
in patients with HU and 19% lower risk of death in 
patients with gout.
Allopurinol and CAD
The key role of six-weeks treatment with al-
lopurinol (600 mg daily) vs. placebo in a small ran-
domized controlled trial (RCT) of 65 patients (aged 
18–85 years) who had angiographically documented 
CAD, a positive exercise tolerance test, and stable 
chronic angina pectoris showed that allopurinol vs. 
placebo increased the median time to ST depres-
sion to 298 s (interquartile range [IQR] 211–408) 
vs. 249 s (IQR 200–375, p = 0.0002) [136]. Simi-
larly, a small, randomized, double-blind, placebo-
-controlled study (n = 65) in patients with CAD 
and LV hypertrophy [137] proved a significant 
reduction of LV mass and LV end-systolic volume in 
patients receiving 600 mg of allopurinol vs. placebo 
(–5.2 ± 5.8 g vs. –1.3 ± 4.48 g, p = 0.007; –2.81 ± 
± 7.8 mls vs. +1.3 ± 7.22 mls, p = 0.047, respec-
tively) [137]. Higgins et al. [138] in a systematic 
review and meta-analysis of 40 studies confirmed 
that XOI improves endothelial function and reduces 
markers of oxidative stress. A steep-dose response 
relationship between allopurinol and endothelial func-
tion has been presented and described showing the 
mechanistic effect of vascular oxidative stress [139].
Allopurinol and congestive HF
In a large observational study of patients with HF 
and a history of gout (n = 25,090), > 30 day-therapy 
with XOI was associated with reduced readmissions 
to hospital, caused by HF or death (adjusted RR 0.69; 
95% CI 0.60–0.79, p < 0.001), and all-cause mortal-
ity (adjusted RR 0.74; 95% CI 0.61–0.90, p < 0.001) 
[111]. In contrast, investigators from Oxypurinol 
Therapy for Congestive Heart Failure (OPT-CHF) 
study did not find clinical improvements in the unse-
lected patient cohort in a group of patients (n = 405) 
with moderate-to-severe HF (New York Heart Asso-
ciation [NYHA] functional class III/IV) due to systolic 
dysfunction. Data from EXACT-HF study, involving 
patients (n = 253) with symptomatic HF, left ven-
tricular ejection fraction (LVEF) ≤ 40%, receiving 
allopurinol (600 mg daily) for 24 weeks showed no 
improvement in LVEF and no significant difference in 
clinical status between the allopurinol- and placebo-
treated patients (worsened: 45% vs. 46%, unchanged: 
42% vs. 34%, improved: 13% vs. 19%, respectively; 
p = 0.68) [140]. 
Interestingly, the post-hoc analysis from OPT-
-CHF suggested that sUA reduction due to oxypu-
rinol correlated with favorable clinical response 
[141–144] and that sUA may serve as a biomarker 
to target XO inhibition in congestive HF. These 
results show the positive potential role of an early 
intervention of implementing the ULT in patients 
with congestive HF.
Allopurinol and hypertension
An ample amount of studies investigated 
the effect of XOI on hypertension. In the United 
Kingdom Clinical Practice Research Datalink, al-
lopurinol use was independently associated with 
a fall in both SBP and DBP [145]. In the short-term, 
crossover study presenting preliminary results in 
adolescents with newly diagnosed hypertension, 
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treatment with XOI resulted in a lowering of BP. 
Treatment with allopurinol (200 mg twice a day 
for 6 weeks) vs. placebo caused a mean change in 
SBP (–6.9 mmHg, 95% CI –4.5 to –9.3 mmHg vs. 
–2.0 mmHg, 95% CI 0.3 to –4.3 mmHg, p = 0.009) 
and DBP (–5.1 mmHg, 95% CI –2.5 to –7.8 mmHg 
vs. –2.4 mmHg, 95% CI 0.2 to –4.1 mmHg, p = 
= 0.05) [146]. In meta-analysis of 10 clinical studies 
with 738 participants treated with allopurinol, SBP 
decreased by 3.3 mmHg (95% CI 1.4–5.3 mmHg, 
p = 0.001) and DBP by 1.3 mmHg (95% CI 0.1–2.5 
mmHg, p = 0.03) [147]. These findings represent 
a new potentially positive therapeutic result which 
requires confirmation in future larger clinical trials.
Whether sUA level is a causative mediator of 
increased BP and impaired vascular compliance 
remains unclear. However, in the study of treated 
hypertensive patients, allopurinol increased aortic 
compliance irrespective of the antihypertensive 
drugs used [148]. This is in line with the observa-
tion that inhibition of XO with allopurinol signifi-
cantly reduces arterial wave reflection measured by 
augmentation index, a marker of arterial stiffness 
in stroke survivors [149].
In a randomized, double-blinded, placebo-
controlled trial, two mechanisms of sUA reduc-
tion were investigated in prehypertensive, obese, 
adolescents, aged 11–17 years by using XOI or 
probenecid. Subjects treated with ULT experienced 
a reduction in clinical SBP 10.2 mmHg and DBP 
9.0 mmHg. ULT also resulted in a significant reduc-
tion in systemic vascular resistance. This data indi-
cates that, at least in young patients with prehyper-
tension, their sUA level influences the BP and that 
it can be significantly reduced by ULT [147, 150].
In a new retrospective analysis of Survival 
of Myocardial Infarction Long-Term Evaluation 
(SMILE studies), researchers evaluated the 1-year 
combined occurrence of MACE, death or hospi-
talization for CV causes in patients after acute MI 
using angiotensin converting enzyme inhibitors 
(ACEI), such as zofenopril or captopril, plus XOI. 
The rate of survival free from MACE was signifi-
cantly higher in a group of patients from the XOI-
-arm than with other ACEI with no XOI (HR 2.29, 
1.06–4.91, p = 0.034). Survival time without any 
events was longer in patients treated with zofeno-
pril and XOI than in those treated with a placebo or 
other ACEI without XOI (log rank test, p = 0.033) 
[151]. The survival benefit of XOI therapy has been 
proven in another RCTs and cohort studies [152]. In 
a recent study published in “Hypertension” allopu-
rinol lowered BP in adolescents and was associated 
with a significantly lower risk of both stroke (HR 
0.50, 95% CI 0.32–0.80) and major cardiac events 
(HR 0.61, 95% CI 0.43–0.87). High-dose treatment, 
i.e., ≥ 300 mg daily, was associated with a lower 
risk of stroke (HR 0.58, 95% CI 0.36–0.94) and 
major cardiac events (HR 0.65, 95% CI 0.46–0.93). 
Summarizing, a decrease in sUA levels, 
achieved by treating patients with ULT, mainly XOI, 
has, in general, been associated with an improve-
ment in CV effects and amelioration in BP control 
[62, 118], but further large studies are essential 
[128]. Nevertheless, allopurinol may also be con-
sidered in hypertensives with asymptomatic HU, 
particularly those at high CV risk. Among the drugs 
recommended for the treatment of co-morbidities 
with HU, great attention should be paid to the key 
drugs that influence sUA levels (Table 1) [153–159]. 
Allopurinol and renal function
It has been known for a long time, that therapy 
with XOI might essentially improve renal func-
tion [4]. A comprehensive meta-analysis of RCTs 
revealed statistically significant improvement in 
eGFR and serum creatinine after ULT, favoring 
the strategy with allopurinol [160]. Goicoechea 
et al. [161] documented the slower progression 
of CKD and reduction of the rate of proteinuria in 
the group randomly assigned to the arm with XOI 
vs. placebo. Another meta-analysis confirmed that 
ULT decreases the risk of kidney failure events and 
end-stage renal disease (ESRD) by 55% (RR 0.45, 
95% CI 0.31 ± 0.64) and 41% (RR 0.59, 95% CI 
0.37 ± 0.96, respectively), compared with standard 
treatment or placebo [162]. Siu et al. [163] reported 
a decrease in sUA levels and preservation of renal 
function in patients treated with XOI at 12 months. 
The meta-analysis of 12 studies by Sampson et 
al. [164] (n = 1187) in a wide range of patients 
revealed improved renal function by ULT at one 
year assessed by the reduced serum creatinine and 
raised eGFR. In another population-based cohort 
study (n = 111,992) investigating the association 
between HU and renal disease, patients treated 
with ULT who achieved sUA level of 6 mg/dL 
showed a 37%-outcome reduction defined as GFR 
reduction of ≥ 30% or endstage renal disease [165].
Febuxostat: Causes more harm  
to cardiovascular patients than  
clinical benefits
In 2009, a new drug, febuxostat, was approved 
by the USA Food and Drug Administration (FDA). 
Febuxostat is a nonpurine XOI and provides highly 
selective and potent inhibition of XO and greater 
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hypouricemic activity vs. commonly used doses 
of allopurinol. Unexpectedly, in 2017 the FDA 
alerted the public that preliminary results from 
a safety clinical trial show an increased risk of 
cardiac death with febuxostat vs. allopurinol. The 
first reports suggested a modestly higher rate of 
CV events with febuxostat [166]. Consequently, 
a large-scale, intensive RCT was designed (CARES) 
to investigate whether febuxostat remains non-
-inferior to allopurinol with regard to MACE in 
patients with gout and high CV risk [117]. In the 
meantime, a meta-analysis of 35 studies did not 
show a significant difference between febuxostat 
and allopurinol in CV events (RR 1.69, 95% CI 
0.54–5.34, p = 0.37) [126]. Moreover, ULT with 
febuxostat reduced the renal decline in subjects 
with gout [167]. In the multicenter FEATHER 
study, where patients (n = 467) were randomly 
assigned in a 1:1 ratio to receive febuxostat or 
placebo for 108 weeks, febuxostat did not mitigate 
the decline in kidney function in patients with stage 
3 CKD and asymptomatic HU [168]. 
Interestingly, during the European Society of 
Cardiology scientific sessions in 2018 the results 
of FREED study were announced, where over 1000 
elderly patients with HU, defined as sUA level 
> 7.0 mg/dL up to 9.0 mg/dL, with one or more 
risks for cerebral, cardiovascular, or renal disease 
were treated with febuxostat (up to 40 mg daily) 
or non-febuxostat (non-treatment or low 100 mg 
daily of allopurinol). Febuxostat lowered sUA level 
to mean 4.5 ± 1.5 mg/dL, while non-febuxostat 
group achieved only 6.76 ± 1.45 mg/dL. After 
3 years, 25% relative risk reduction in the compos-
ite of death to any cause, cerebrovascular disease, 
non-fatal CAD, HF requiring hospitalization, the 
arteriosclerotic disease requiring treatment, renal 
impairment, and atrial fibrillation was observed in 
febuxostat group compared to the non-febuxostat 
group. Febuxostat also prevented the development 
and progression of CKD in this study. Notably, 
renal impairment was the only significantly dif-
ferent event, at 16.2% in the febuxostat group 
vs. 20.5% in the control group (HR 0.745, 95% CI 
0.562–0.987). There was no difference in CV clini-
cal outcomes examined separately with febuxostat 
vs. control treatment. Herewith we should depict 
that only 27% of patients in the non-febuxostat 
group received allopurinol and more studies are 
warranted to confirm these results [Kijoma S, ESC 
Congress 2018]. The question remains whether 
the mortality results of the CARES trial are due 
to beneficial effects of allopurinol or deleterious 
effects of febuxostat.
In the last report, with findings from 32 months 
follow up (n = 6190), CARES investigators con-
firmed that all-cause and CV mortality were higher 
in the febuxostat group than in the allopurinol 
group (HR for death from any cause 1.22, 95% 
CI 1.01–1.47; HR for CV death 1.34, 95% CI 
1.03–1.73) [117]. 
The first phase 3 RCTs, unfortunately, pro-
vided a false hope that febuxostat was safe that 
led to the FDA-approval. As a result, febuxostat 
has been prescribed to hundreds of thousands of 
patients over the past decade who were unaware of 
the potential danger. Since the last CARES report 
published in 2018, strong evidence has emerged 
that the serious CV harms of febuxostat substan-
tially outweigh any purported clinical benefit [117]. 
Thus, based on CARES study, treatment with 
febuxostat in patients at high CV risk should not 
be recommended.
Management strategies:  
Current recommendation for  
the treatment of patients  
with increased sUA levels (Fig. 3)
The primary aim of treatment of HU is to lower 
the sUA level (STEP 1). The measurement of sUA 
concentration was included in routine tests by ex-
perts of both the European Society of Cardiology 
and European Society of Hypertension. 
Our recommendation, based on the available 
data and a number of available guidelines, points 
to an optimal target of sUA level at 6 mg/dL (360 
μmol/L) which is in line with the 2016 evidence-
based recommendation for the management of gout 
of patients on ULT. Thus, sUA levels should be 
monitored and maintained at < 6 mg/dL [169]. It is 
also in accordance with the 2012 American College 
of Rheumatology (ACR) Guidelines, which indicate 
ULT for people with symptomatic HU and recom-
mends a target sUA level of less than 360 μmol/L 
(6 mg/dL) for all patients on ULT [170]. Accord-
ing to the British Society for Rheumatology, gout 
management by rheumatologists from the United 
Kingdom concords well with guidelines for most 
audit standards. Of note, 2016 guideline points 
to a lower sUA target (< 5 mg/dL; 300 μmol/L) 
for patients with severe gout in order to facilitate 
faster dissolution of UA crystals, especially when 
tophi, chronic arthropathy, or frequent attacks 
occur, until a total crystal dissolution and resolu-
tion of gout. Furthermore, the British Society of 
Rheumatology recommends a target of sUA of 
< 5 mg/dL for all patients with gout [171]. Notably, 
www.cardiologyjournal.org 555
Claudio Borghi et al., Expert consensus for patient with hyperuricemia and high cardiovascular risk
the PAMELA study supported the sUA level of ca. 
5 mg/dL in patients at high CV risk. Thus, based 
on current knowledge, in our opinion, one should 
consider sUA target of < 5 mg/dL in patients with 
high CV risk comprising at least two of the follow-
ing: hypertension, diabetes, dyslipidemia, recent 
stroke or MI, CKD and < 6 mg/dL for patients 
not suffering from the above. Still, more RCTs are 
needed to support this opinion.
While optimizing the management strategy of 
HU, great attention should be paid to the key drugs 
prescribed due to comorbidities that may substan-
tially influence sUA levels (Table 1, STEP 2). 
Especially since a large body of literature con-
firms that HU coexists with a wide variety of 
microvascular- and macrovascular diseases in-
cluding hypertension [4], metabolic syndrome 
[48], CKD [53] or other CVD [54, 55] and these 
comorbidities increase the incidence of HU [4]. 
Consequently, the management of such conditions 
should be an integral part of a patients’ treatment 
strategy (Table 2).
As previously reported, also in the United 
Kingdom, less than half of the patients treated 
achieved the desired sUA levels during 12 months 
of treatment. Desired sUA levels ≤ 6 mg/dL and 
< 5 mg/dL were achieved by 45% and 25% of 
patients, respectively [172]. In a cohort study 
including 6042 patients, among 1035 allopurinol 
users, less than half (44.7%) reached target urate 
concentration [133]. 
Thus, we conclude that doctors often un-
derestimated HU. An important step toward im-
proved management of HU/gout in clinical routine 
is to improve adherence to guidelines, raising 
awareness of HU and associated comorbidities, 
prompting specific monitoring and treatment of 
these, as well as building multidisciplinary teams 
for optimal diagnostic and management strategy 
(STEP 3). 
Recommended life-style changes (STEP 3)
The following dietary factors have shown an 
adverse effect on sUA levels: low-sodium diet 
[173], consumption of red meat, seafood, fructose, 
and sugar-sweetened beverages, alcohol [174]. Di-
etary factors known to decrease sUA include coffee, 
dairy products, cherries [155, 175], and ascorbic 
acid [176]. Some studies have also confirmed that 
weight loss and regular physical activity are effec-
tive in reducing sUA levels [177, 178]. Therefore, 
maintenance of healthy weight and an increase in 
physical activity should be strongly recommended. 
Patients with a high concentration of sUA should 
avoid, fructose-rich and animal-derived high purine 
meals and alcohol.
556 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 5
Figure 3. Management strategy for patients suffering from hiperuricemia. CV — cardiovascular; CKD — chronic kidney 
disease; MI — myocardial infarction; SUA — serum uric acid.
Xantine oxidase inhibitors:  
First-line therapy (STEP 4)
As mentioned above, XOI, especially allopurinol, 
are recommended as a first-line ULT. They are rap-
idly metabolized to oxypurinol, which is eliminated by 
the kidneys, therefore this requires dose adjustment 
according to renal function [169]. According to the 
Summary of product characteristics of allopurinol in 
patients with CKD, the maximum allopurinol dos-
age should be adjusted to eGFR [169]. The recom-
mended initial allopurinol dosage is 100 mg daily, with 
a gradual titration, e.g. 300–600 mg daily, up to the 
achievement of the desired sUA target level [169].
In accordance to meta-analysis, which included 
15 papers concerning allopurinol, 44.4% of patients 
reached the target of sUA with this therapy and 
the average reduction in sUA was 33.8% [179]. 
If the sUA target cannot be achieved, the patient 
should be switched to benzbromarone with or 
without allopurinol (STEP 5), except in patients 
with eGFR of < 30 mL/min [180]. Although there 
is growing evidence of a benefit of a high-dose al-
lopurinol regimen, i.e. ≥ 600 mg daily, especially 
in patients with high levels of sUA, we should still 
be aware of rare complications. Physicians should 
carefully consider dose escalation to achieve opti-
mal treatment goals, especially due to allopurinol 
hypersensitivity syndrome or severe cutaneous 
allergic reactions (SCARs) — which usually occur 
after 8 weeks of therapy [181–183]. Several factors 
contribute to the development of this syndrome, 
including initial doses which are too high, CKD, 
accompanying use of diuretics, the presence of 
HLA-B*5801 [184, 185]. 
As mentioned above, XOI improves endothe-
lial function [138, 186], oxidative stress markers, 
as well as cardiac physiology, including LVEF [187], 
cardiac index [187], end-systolic volume [188], 
and myocardial efficiency [189]. Thus, allopurinol 
may be considered in hypertensives with asympto-
matic HU, particularly those with CVD. Although 
high-dose allopurinol defined as ≥ 300 mg/dL is 
associated with reduced risk of all-cause mortality 
[7, 134], consideration of optimal dose seems to be 
a major factor in the design of future research.
Febuxostat
Febuxostat, as a non-purine selective XOI, 
is metabolized in the liver and excreted by the 
kidneys. A side effect of febuxostat can be adverse 
skin effects. Previously, dose-adjusted febuxostat 
was considered in cases where the sUA target 
could not be achieved with allopurinol. Based on 
the meta-analysis of 16 papers, including febuxostat 
treatment, 70.3% of patients on febuxostat reached 
the target of sUA (6 mg/dL) and the reduction in 
sUA was 45.3% with respect to baseline values 
[179]. In first studies, febuxostat (dose of ≤ 120 
mg/day) resulted superior over allopurinol (dose 
≤ 300 mg/day) in terms of probability to achieve 
the recommended target of sUA (OR 2.64, 95% CI 
1.74–4.01) and percentage reduction of uricemia 
(mean difference: 13.08, 95% CI 7.6–18.55). Fur-
thermore, febuxostat showed better results than 
allopurinol in patients with CKD (OR 0.85, 95% CI 
0.75–0.97) [120, 179].
However, the safety concerns are already 
raised after results in patients with gout and CVD. 
Thus, due to substantially higher all-cause and 
cardiovascular mortality rate in the febuxostat 
group vs. as compared to in the group receiving al-
lopurinol [117] febuxostat cannot be recommended, 
especially in patients at high CV risk. 
Lesinurad
Lesinurad is an oral selective inhibitor of URAT1 
and OAT4 renal transporters, which increases renal 
UA excretion and lowers sUA levels by inhibiting 
UA reabsorption. A dose of 200 mg daily is recom-
mended in combination with XOI in patients who do 
not achieve treatment targets. Lesinurad can increase 
efficiency compared to XOI applied alone or prevent 
maximal doses of XOI [190]. In a CLEAR study, les-
inurad of 200 mg or 400 mg together with allopurinol 
significantly increased the proportion of patients who 
achieved the sUA target level compared to allopurinol 
(54.2%, 59.2%, and 27.9%, respectively, p < 0.0001) 
[191]. Similarly, the combination of lesinurad at 
200 mg and 400 mg and maximum dose of febuxostat 
for 12 months compared to febuxostat monotherapy 
was more efficient in achieving sUA target levels in 
the CRYSTAL trial [192, 193].
To summarize, lesinurad in combination with 
an allopurinol is a novel option for the treatment 
of HU in adults with gout who have not achieved 
their target sUA levels with allopurinol alone 
[194]. Results from three clinical studies investi-
gating the effectiveness of lesinurad suggest the 
addition of lesinurad to allopurinol or febuxostat 
is superior to XOI monotherapy in reducing sUA 
concentrations. However, this therapy increased 
the risk of renal-related adverse events. Thus, 
the recommendation is to use lesinurad 200 mg 
orally per day, in combination with an XOI, among 
patients with adequate renal function (i.e., above 
45 mL/min) in cases with inadequately controlled 
HU associated with gout, should be treated with 
allopurinol (STEP 5) [193]. 
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Once the sUA target is achieved continuously, 
the dose of ULT should be maintained indefinitely 
with ongoing monitoring of sUA levels twice 
a year (STEP 5).
Many unresolved questions remain:  
Areas in need of further study
The prooxidant and antioxidant effect make 
the role of sUA complex. Furthermore, whether 
sUA is an independent risk factor of hard endpoints 
remains unclear and has been further complicated 
by the interaction of sUA levels and renal function. 
Thus, the role of sUA in patients and its influence 
on their CV system has not been discovered. The 
superiority of XOI over uricosuric agents is due 
to potential inhibition of ROS production and its 
antioxidant effect. The treatment target based on 
the solubility of UA may need to be reconsidered, 
especially since data from PAMELA study identified 
a lower clinically meaningful cut-off level of sUA, 
i.e. < 5 mg/dL, and even lower for women. Uptill 
now a patients’ sUA level is not taken into consid-
eration in the algorithm for assessing their total 
CV risk. Last, but by no means least, there is no 
evidence to support the treatment of asymptomatic 
HU, although, a large body of evidence does show 
the beneficial effect of ULT on CV results. In this 
light, when HU accompanies other CV risk factors, 
therapy with XOI should at least be considered.
Most relevant recommendations:  
The take home message  
for the clinical practitioners
A remarkable number of epidemiological stud-
ies have demonstrated that HU is strongly related 
to increased CV risk and predicts CV mortality 
and morbidity in such diseases as hypertension 
or diabetes. The fact that there is a significant 
increase in the onset of newly diagnosed hyperten-
sion, metabolic syndrome in healthy patients with 
elevated levels of sUA, its role has been proved 
to be an independent risk factor in CV patients. 
Therefore, all considerations presented, point to 
the need for greater attention to monitoring sUA 
levels when diagnosing patients, not only from 
a rheumatological standpoint but also regarding 
CV and renal risk, including eGFR measurements 
[4, 195]. This will play a key role in the prevention 
of CVD and improve future treatment strategies. 
The need for active screening of CV risk factors 
in patients who had been diagnosed with gout is 
highly recommended both by the ACR and The 
European League Against Rheumatism (EULAR) 
[169, 196, 197]. 
In conclusion, we would like to summarize 
our recommendations which should be helpful to 
clinicians treating with patients suffering from HU 
who also have a high CV risk:
 — All patients with HU should be informed about 
pharmacological and epidemiological factors 
influencing HU, comorbidities, and the CV 
risk factors.
 — All patients should receive precise informa-
tion about required lifestyle modification, 
modification to their diet, a need for weight 
loss if necessary, and strict adherence to rec-
ommended treatment 
 — Physical activity increase to a moderate level 
is strongly recommended.
 — As we have established that the sUA level in 
CV patients contributes to the identification of 
patients at high risk, they should be regularly 
monitored.
 — Both patients and physicians, including pri-
mary care physicians, should strive to obtain 
and maintain lifelong sUA levels lower than 
6 mg/dL. In cardiovascular patients the target 
level should be < 5 mg/dL.
 — As soon as a diagnosis of HU is reached, ULT 
with XOI should be prescribed. Consider start-
ing allopurinol 100 mg daily, then titrate to 
300–600 mg daily to reach the targets.
 — Once the desired sUA target is achieved, the 
dose of ULT should be maintained indefinitely 
and the patient’ sUA level should be monitored 
twice a year.
 — A dosage of allopurinol of 300–600 mg/daily 
is recommended. If it is not tolerated by the 
patient or desired target of sUA is not reached, 
the combined therapy of allopurinol + uricos-
uric/lesinurad, should be prescribed.
 — In patients with renal impairment, the allopu-
rinol dosage should be adjusted to eGFR.
 — In patients with HU receiving diuretics, treat-
ment modification is needed.
 — Febuxostat should be avoided, especially in 
patients with a high CV risk.
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